Open AccessAdalimumab Treatment of Life‐Threatening Tuberculosis
Author(s) -
Robert S. Wallis,
Cloete van Vuuren,
Samantha Potgieter
Publication year - 2009
Publication title -
clinical infectious diseases
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/598504
Subject(s) - adalimumab , medicine , discontinuation , tuberculosis , tumor necrosis factor alpha , tumor necrosis factor α , necrosis , immunology , surgery , pathology
Most guidelines call for the discontinuation of treatment with tumor necrosis factor blockers in patients who develop tuberculosis. We report a case of life-threatening tuberculosis paradoxical reaction involving the lungs caused by withdrawal of the anti-tumor necrosis factor antibody adalimumab. Clinical improvement occurred only after resumption of adalimumab treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom